Stay updated on Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check20 days agoChange DetectedThe page revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedThe study EV-103 (NCT03288545) was terminated by the sponsor after meeting enrollment targets and primary objectives, with data collected for planned regulatory filings. The page updates recruitment status to reflect termination, including removal of the 'Active, not recruiting' designation and related dates.SummaryDifference0.2%

- Check49 days agoChange DetectedAdded revision: v3.5.0. Removed revision: v3.4.3.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check85 days agoChange DetectedPage now shows Revision: v3.4.2. The funding-lapse notice and the prior Revision: v3.4.1 text were removed.SummaryDifference0.2%

Stay in the know with updates to Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.